Japanese-headquartered Chugai Pharmaceutical has already developed world-class technologies for antibody engineering and mid-size molecule drug discovery which can reach some intracellular targets that were previously difficult to access, and have high binding activity, and good oral absorption. Chugai Pharma has been operating in Singapore since 2012 as a subsidiary, Chugai Pharmabody Research (CPR) developing innovative pharmaceutical products in collaboration with Singapore’s biopharma R&D ecosystem. In an interaction with BioSpectrum Asia, Dr Hisafumi Yamada, Executive Vice President (R&D) at Chugai Pharmaceutical, echoes CRP’s enduring association with the regional biopharma industry on the occasion of completing a decade of presence in Singapore. Edited excerpts;
How significant is the development of mid-size molecule drugs relative to small molecule and antibody modalities to address unmet medical needs?
With mid-size molecule technology, we aim to discover new pharmaceutical drugs that act against intracellular tough targets which are unreachable with small molecules or therapeutic antibodies.
Though they are the most common modalities among pharmaceutical drugs, antibodies can target only extracellular molecules (approximately 20 per cent of all proteins), and small molecules target only molecules with pockets (approx. 20 per cent of all proteins).
It is said that there may be approximately 2,000 proteins involved with disease. However, new drugs launched within the last 10 years target only about 50 of these proteins. Many are still considered undruggable,” as they are difficult to reach by either small molecules or antibodies. We must find a way to reach these tough targets so that we can create innovative new drugs for patients with diseases where there are limited treatment options and high unmet medical needs.
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber ? Sign In
This story is from the {{IssueName}} edition of {{MagazineName}}.
Start your 7-day Magzter GOLD free trial to access thousands of curated premium stories, and 9,000+ magazines and newspapers.
Already a subscriber? Sign In
"We are dedicated to helping people of all ages see brilliantly"
The global leader in eye care for over 75 years, Alcon Inc. strives to help eye care professionals strengthen their practices and serve patients better, improving visual health worldwide. Through its innovative eye care portfolios, Alcon has established operations in 56 countries and serves patients in 140 countries. Jason Hoffe, Vice President, APAC Vision Care, Alcon, responsible for driving the vision care business in the region shares opportunities exist for the company and new developments in eye healthcare that are cause for optimism for patients in the region.
Singapore Turns Tech Beacon with Revolutionary Pharma Manufacturing & Digital Transformation
In the current pharmaceutical manufacturing environment, linking information technology (IT) with operational technology (OT) systems is increasingly vital. This integration enables a seamless exchange of information between these two historically separate domains - one focused on data management and the other on overseeing physical operations. This enables various aspects of the manufacturing process to gain insights from one another to boost efficiency and refine strategic decision-making. Digital transformation is essential for directing companies through the complexities of implementation and ensuring a seamless shift to a data-driven, digitally optimized manufacturing landscape.
Building the Future of Medicine
PRODUCT OF THE YEAR 2024 - Needle Free Injection System technology by IntegriMedical
Emerging Leader in Cell & Gene Therapy
STARTUP OF THE YEAR 2024 - ImmunoACT
Improving Access for Respiratory Healthcare
STARTUP OF THE YEAR 2024 - Aevice Health
Making an Impact with a 'CliKX'
Dr Lynne Lim, Co-Founder & Chief Executive Officer, NousQ
Eyeing 20-20 Vision of Excellence
Dr Jogin Desai, Co-Founder & Chief Executive Officer, Eyestem Research
Refining the Use of Radiation
Dr Christian Behrenbruch, Managing Director and Group Chief Executive Officer (CEO), Telix Pharmaceuticals
Honouring Innovators in Asia's Thriving Life Sciences Sector
Asia has, indeed, become the new hub for growth and innovation, with no signs of losing steam. To recognise the Asian companies and individuals for their commendable performance and achievements during 2023 and 2024, BioSpectrum Asia Excellence Awards 2024 ceremony was held at Hotel Fort Canning in Singapore on December 6, 2024.
How To Control Indian Diabetes Growth
World Diabetes Day, observed on November 14, reminds us of the growing impact of diabetes on global health and the urgent need for collective action to prevent, diagnose, and manage this chronic condition. In 2024, the theme 'Breaking Barriers, Bridging Gaps' underscores the critical importance of accessible, high-quality diabetes care, especially for underrepresented communities. The Government of India has taken many measures intending to reduce the prevalence of diabetes and alleviate its long-term complications, contributing to a healthier future for all citizens.